Overview

3BP's targeted radiopharmaceuticals provide a focused and personalized approach to the treatment of cancer.

Peptides and peptidomimetics constitute excellent tumor-specific targeting moieties and can be coupled to therapeutic and diagnostic radioisotopes via a linker and a chelator.

Radiolabeled peptidomimetics specifically bind target-expressing tumor cells and kill these as well as neighboring tumor cells by direct radiation-induced cell damage and via the bystander and cross-fire effect.

Using 3BP's theranostic approach, you can see where your drug is going and monitor the efficacy of the treatment. This allows the identification of responders leading to faster and cost-efficient clinical trials and increased chances of successful treatment.

It also allows personalized dosing based on individual imaging data, thus achieving maximal therapeutic effect with minimal unwanted side effects.

For a popular scientific introduction to Nuclear Medicine see the documentary. "What is Molecular Nuclear Medicine? From the history of radioactivity and cancer to the most modern theranostic treatments."

With kind permission from AAA.

Peptidomimetic tracers. Cancer drug development at 3BP.